Board of Directors

Shareholdings are correct as at May 27 2020, and are updated every year.

Bert Junno

Chairman of the board since 2020

Born: 1966

Education and experience: Bert has previous management and board level experiencefrom several European and US based companies in fields of electronics, biotech and IT. He is a co-founder of several life science companies including WntResearch AB, Galecto Biotech AB, Gabather AB, Aptahem AB and Cyxone AB. Bert Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.

Current assignments: Chairman of the Board of Cyxone AB (publ). Board member of Accequa AB and Accequa GmbH.

Previous assignments: Board member of Taurus Energy AB (publ), Cardiovax llc., Galecto Biotech AB, Aptahem AB (publ), CEO and Board member of WntResearch AB (publ) and Gabather AB (publ). Member of the advisory board of the Swedish patent office 2010-2019.

Own and/or related parties’ holdings in the company: Holds no shares or warrants.

Independent of the company and the management, independent of the major owners of the company.

Jan Nilsson

CEO of CombiGene AB (publ) since 2016
Born:1949

Education and experience: Jan Nilsson has an MA from the University of Gothenburg and an MBA from Uppsala University. Jan was appointed CEO of CombiGene on 1 October 2016. He has long-standing experience from large pharmaceutical companies and biotech firms. He has also been active in several different areas in the pharmaceutical industry such as pharmaceuticals development and the launch, sales and marketing of established international brands. He also has a solid management background, having served as CEO of both private and public-sector companies.

Current assignmentsBoard member of CanImGuide Therapeutics AB, Urbicum Ledningskonsult AB and Panion Animal Health AB.

Previous assignments: CEO of NeuroVive Pharmaceutical AB.

Own and/or related parties’ holdings in the company: 500,000 shares. 127,760 warrants of series TO3 and 127,760 warrants of series TO4.

Independent of the company and the management, independent of the major owners of the company.

Peter Nilsson

Board member since 2014
Born: 1970

Education and experience: Peter has a long background in finance and is currently working as a CFO with a focus on strategic and business development in the Rotorbulk Group, also known as Finja. Previously,Peter was a partner and business area manager at Mazars SET Revisionsbyrå AB. As an auditor, Peter has worked with both owner-managed and public companies, and has conducted exchange audits prior to listing on the NGM stock exchange. He was also director of Corporate Finance at Mazars, focusing on acquisitions and due diligence. Peter received his M.Sc. in Business Administration and Economics from Lund University and was a certified public auditor.

Current assignments: Board member and owner of PN Finanskonsult AB and Chairman of the Board of Flisby AB.

Previous assignments: Board member of VA Automotive AB (publ) and Chairman of the Board of Åhus Åkeri AB.

Own and/or related parties’ holdings in the company: 1,076,002 shares. 150,000 warrants of series TO3 and 150,000 warrants of series TO4.

Independent of the company and the management, independent of the major owners of the company.

Jonas Ekblom

Board member since 2020

Born: 1965

Education and experience: Jonas has worked over 25 years in the life science sector. He is currently the
CEO of Promore Pharma and has previously held senior and executive roles in biotech companies in Sweden, US and Switzerland including Pharmacia, Biovitrum, Sequenom and Invitrogen and BOWS Pharmaceuticals SA. He is an Associate Professor in Pharmacology at Uppsala University, has a B.Sci. in Chemistry from Stockholm
University, a Ph.D. in Experimental Neurology from Uppsala University, and post-doctoral studies from University of Southern California, School of Pharmacy in LA. He has also received professional training in strategic planning and business management. Jonas has published more than 60 articles in peer-reviewed journals.

Current assignments: CEO of Promore Pharma AB (publ). Board director in World 5 Ventures and Pergamum AB. Chairman of the board in EffRx Pharmaceuticals SA. Edge of the World Strategies Corporation (own consultancy company).

Previous assignments: Board director in Orin Pharmaceuticals SA, KLIFO A/S, Axelar AB and The Releef Initiative.

Own and/or related parties’ holdings in the company: Holds no shares or warrants.

Independent of the company and the management, independent of the major owners of the company.

Per Lundin

Board member since 2020

Born: 1983

Education and experience: Per has over 10 years of experience in advising, founding and leading biotech companies, leveraging his deep expertise across corporate strategy, scientific leadership, legal &intellectual property and business development. Per is co-founder and COO of UK-based Evox Therapeutics. Prior to founding Evox, Per co-founded and served as CEO of IsletOne Therapeutics, a cell therapy company spun out of the Karolinska Institute. Previously, Per managed a European business development channel for Thomson Reuters IP & Science and before that qualified as a European Patent Attorney, starting out in the biotech practice of one of the largest European IP law firms. He started his career as a research scientist with the Australian biotech company Apollo Life Sciences, working on nanoparticle drug delivery. Per earned his Ph.D. at the Karolinska Institute, holds an MSc in Biotechnology Engineering, and an MScBA from Stockholm University School of Business.

Current assignments: Board member of Evox Therapeutics Ltd.

Previous assignments: Board member of IsletOne AB. Owner and active in the following companies: Evox Therapeutics Ltd.

Own and/or related parties’ holdings in the company: Holds no shares or warrants.

Independent of the company and the management, independent of the major owners of the company.

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook